Recent developments include expansion of the PrecisionCHD test launch in India, telehealth agreements with Navierre, securing final CMS pricing determinations, and Nasdaq compliance after a reverse stock split.

• Cardio Diagnostics expanded its global footprint and launched PrecisionCHD in India, leading to a stock surge [N1].
• The company signed a nationwide telehealth agreement with Navierre to broaden access to its diagnostic tests [N6][N7].
• Cardio secured final CMS pricing determinations for its PrecisionCHD and Epi+Gen CHD tests, supporting reimbursement efforts [N4].
• The company regained Nasdaq compliance following a reverse stock split, maintaining its listing status [N2].
• Cardio filed to sell 1.24 million shares of common stock for holders, indicating ongoing capital raising activities [N5].

Cardio Diagnostics leverages cutting-edge AI and epigenetics technology to offer differentiated clinical tests addressing major cardiovascular diseases, a leading cause of death and healthcare cost. The company’s proprietary Multi-Omics Engine™ and broad patent portfolio provide a strong foundation for innovation and product development. Securing reimbursement codes and CMS pricing supports commercial viability. Strategic partnerships, including telehealth agreements and international expansion to India, diversify revenue channels and increase market reach. The company’s focus on expanding product offerings to other cardiovascular conditions and building clinical evidence may enhance adoption. The scalable laboratory operations and AI-driven platform position Cardio to address a large and growing market with significant unmet needs.

Cardio Diagnostics operates in a highly competitive and rapidly evolving cardiovascular diagnostics market with established and emerging competitors using various technologies. The company has a limited operating history with nominal revenue and ongoing net losses, and its ability to achieve sustained profitability is uncertain. The commercialization process for diagnostic tests is lengthy and subject to regulatory, reimbursement, and behavioral challenges, which may constrain revenue growth. Cardio faces potential risks related to Nasdaq listing compliance due to market value requirements. The company’s liquidity position shows no cash on hand as of June 30, 2026, which may limit operational flexibility. Market acceptance, reimbursement coverage, and successful execution of strategic initiatives remain uncertain and could adversely affect business performance.

Cardio Diagnostics’ moat is anchored in its proprietary AI-driven Multi-Omics Engine™ technology, which integrates genetic and epigenetic biomarkers to develop unique diagnostic tests for cardiovascular diseases. The company holds a broad intellectual property portfolio with issued patents and numerous pending applications protecting its technology and products across multiple jurisdictions. Its tests are among the first epigenetics-based clinical diagnostics for heart disease, offering dynamic biomarker assessment that can potentially personalize interventions. The company’s CLIA-certified laboratory and secured reimbursement codes provide operational and commercial advantages. Strategic channel partnerships and international expansions further support market penetration. However, the cardiovascular diagnostics market is highly competitive with established players and alternative technologies, which may challenge Cardio’s market share and growth.

• Nasdaq Listing Compliance Risk: The company faces potential delisting from Nasdaq if it fails to meet new minimum market value of listed securities requirements, which could lead to trading on the OTC market with associated liquidity and valuation risks [S2].
• Limited Operating History and Profitability: Cardio has a limited operating history with nominal revenue and significant net losses, and there is uncertainty regarding its ability to achieve or sustain profitability [S1, S2].
• Commercialization and Adoption Challenges: The commercialization lifecycle for diagnostic tests is lengthy and involves regulatory, reimbursement, and behavioral factors that may delay or limit market adoption and revenue generation [S1].
• Competitive Market Environment: The cardiovascular diagnostics market is highly competitive with established and emerging players using diverse technologies, which may impact Cardio’s market share and growth prospects [S1].
• Liquidity and Capital Requirements: As of June 30, 2026, the company had no cash and cash equivalents, relying on capital raises such as at-the-market sales agreements to fund operations, which may pose risks to operational continuity [S2].

• Cardio Diagnostics Holdings, Inc. develops and commercializes AI-driven epigenetics-based clinical tests for cardiovascular diseases (CVD) including coronary heart disease (CHD), stroke, heart failure, and diabetes [S1].
• The company’s core technology is the AI-driven Multi-Omics Engine™, which integrates genetic and epigenetic biomarkers to create diagnostic solutions [S1].
• Cardio launched its first clinical test, Epi+Gen CHD™, in 2021, a symptomatic CHD risk assessment blood test [S1].
• In March 2023, Cardio launched PrecisionCHD™, an integrated epigenetic-genetic blood test for earlier detection of coronary heart disease, coupled with the Actionable Clinical Intelligence (ACI) platform to personalize patient management [S1].
• In May 2023, the company launched CardioInnovate360™, a research-use-only solution for biopharmaceutical discovery and validation related to cardiovascular diseases [S1].
• In February 2024, Cardio launched HeartRisk™, a cardiovascular disease risk intelligence platform designed to augment clinical blood tests [S1].
• Cardio’s tests are categorized as laboratory-developed tests (LDTs) performed in its CLIA-certified high complexity laboratory [S1].
• The company has secured CPT PLA reimbursement codes and final CMS gapfill payment rates of $854 for both PrecisionCHD™ and Epi+Gen CHD™ tests and is pursuing Medicare and commercial payor coverage [S1].
• Cardio has a patent portfolio including seven patent families with issued patents in multiple countries and numerous pending applications protecting its technology and products [S1].
• The company’s business strategy includes expanding product offerings to include tests for stroke, congestive heart failure, and diabetes, expanding clinical evidence, scaling internal operations, and pursuing strategic partnerships or acquisitions [S1].
• Cardio has established strategic channel partnerships to accelerate sales cycles and expand distribution, including international expansion to India and telehealth agreements such as with Navierre [S1, N1, N6, N7].
• The company faces competition from established and emerging companies in cardiovascular diagnostics, including genetic, imaging, proteomic, and other biomarker approaches [S1].
• Cardio has a limited operating history and has incurred operating losses since inception, with nominal revenue generated in 2024 and 2025 and net losses totaling over $14 million for those years combined [S1, S2].
• As of June 30, 2026, Cardio had $0 in cash and cash equivalents, current assets of approximately $6.16 million, current liabilities of approximately $0.36 million, and a strong current ratio of 17.15, indicating liquidity to cover short-term obligations [S2].
• The company’s stock is listed on Nasdaq but faces potential risk related to new minimum market value of listed securities (MVLS) requirements, which could lead to delisting if not met [S2].
• Recent business developments include expansion of the PrecisionCHD test launch in India, telehealth agreements, and securing final CMS pricing determinations for its tests [N1, N4, N6, N7].
• Cardio has sold over 2.25 million shares under its at-the-market sales agreement to raise capital [S1].